Treatment of Pathological Gambling with Disulfiram: A Report of 2 Cases

 

 Buy Article Permissions and Reprints

Introduction

Pathological gambling (PG) is a condition consisting of persistent and repetitive patterns of gambling, often associated with impaired functioning, reduced quality of life, bankruptcy and divorce [1] [2]. The prevalence of PG in the general population is estimated as 0.42% in the U. S. [3], the corresponding rates in Germany range from 0.19 to 0.56% [4]. Although several lines of clinical evidence suggest common features of PG and substance dependence [5], the disorder is currently categorized in the group of “habit and impulse disorders” in ICD-10 [6] and “impulsive control disorders not elsewhere classified” in DSM-IV [7]. Shared characteristics of PG and substance dependence include genetic [8], phenomenological and clinical [9] as well as common neural features, especially alterations of the mesolimbic reward system [10]. An fMRI study reported a reduced activation in the ventral striatum and the ventromedial and ventrolateral prefrontal cortex in patients with PG in the processing of monetary rewards during a gambling paradigm in comparison to healthy subjects [11]. Similar results have been shown in patients with alcohol dependence [12] [13] [14] and cocaine dependence [15], suggesting a common pathophysiological mechanism in both PG and substance dependence and thereby substantiating the understanding of PG as a non-substance-related addiction.

Current treatment approaches for PG include cognitive-behavioral therapy as well as pharmacotherapies using opiate antagonists like naltrexone [16], lithium [17], selective serotonin reuptake inhibitors [18] and the glutamatergic agent N-acetylcysteine [19]. However, the overall effect sizes of these treatment concepts are only modest and approved pharmacotherapies are lacking.

Disulfiram, an aldehyde dehydrogenase inhibitor, is being used for more than 50 years as an aversion therapeutic agent for the treatment of alcohol dependence [20]. Besides this well-known mechanism of action, disulfiram is also able to inhibit the dopamine beta-hydroxylase which metabolizes dopamine to norepinephrine [21]. Via this effect, administration of disulfiram leads to an increase of dopamine concentrations while decreasing the concentrations of norepinephrine in the brain [22] [23]. Based upon the observations that PG is associated with diminished activation of the dopaminergic reward system [11] and elevated levels of norepinephrine or its metabolites in cerebrospinal fluid, plasma and urine [24], disulfiram has been hypothesized to be a new pharmacological treatment option for this disorder [25] [26]. In cocaine dependence, disulfiram has already shown preliminary efficacy in reducing relapse rates. However, there is only low evidence for its broad clinical use until now [27].

In this report, we present 2 cases of patients meeting the diagnostic criteria for PG according to ICD-10 and DSM-IV who received a pharmacotherapy with disulfiram. To assess changes in severity of PG, both patients completed the pathological gambling adaption of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS), a reliable and validated 10-item questionnaire [28], at every visit.

References

• 1 Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling.  Compr Psychiatry. 2005;  46 34-37
  CrossrefPubMedGoogle Scholar
• 2 Argo TA, Black DW. Clinical Characteristics.  In: Grant JE, Potenza MN, editors. Pathological Gambling: A Clinical Guide to Treatment. 2004 pp 39-53
  Google Scholar
• 3 Welte J, Barnes G, Wieczorek W. et al . Alcohol and gambling pathology among U.S. adults: prevalence, demographic patterns and comorbidity.  J Stud Alcohol. 2001;  62 706-712
  PubMedGoogle Scholar
• 4 Meyer G, Hayer T. Problem and pathological gambling: Epidemiology and prevention.  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010; 
  PubMedGoogle Scholar
• 5 Frascella J, Potenza MN, Brown LL. et al . Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint?.  Ann N Y Acad Sci. 2010;  1187 294-315
  CrossrefPubMedGoogle Scholar
• 6 WHO .Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien. 1994. Dilling H, Mombour W, Schmidt MH, Schulte-Warkwort E., eds Huber, Bern;
  Google Scholar
• 7 Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) .4th ed. 1994. Washington, DC., American Psychiatric Association;
• 8 Slutske WS, Eisen S, True WR. et al . Common genetic vulnerability for pathological gambling and alcohol dependence in men.  Arch Gen Psychiatry. 2000;  57 666-673
  CrossrefPubMedGoogle Scholar
• 9 Tavares H, Zilberman ML, Hodgins DC. et al . Comparison of craving between pathological gamblers and alcoholics.  Alcohol Clin Exp Res. 2005;  29 1427-1431
  CrossrefPubMedGoogle Scholar
• 10 Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions.  Biochem Pharmacol. 2008;  75 63-75
  CrossrefPubMedGoogle Scholar
• 11 Reuter J, Raedler T, Rose M. et al . Pathological gambling is linked to reduced activation of the mesolimbic reward system.  Nat Neurosci. 2005;  8 147-148
  CrossrefPubMedGoogle Scholar
• 12 Beck A, Schlagenhauf F, Wüstenberg T. et al . Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics.  Biol Psychiatry. 2009;  66 734-742
  CrossrefPubMedGoogle Scholar
• 13 Martinez D, Gil R, Slifstein M. et al . Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum.  Biol Psychiatry. 2005;  58 779-786
  CrossrefPubMedGoogle Scholar
• 14 Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia – psychopathological and behavioral correlates.  Eur Psychiatry. 2002;  17 9-16
  PubMedGoogle Scholar
• 15 Asensio S, Romero MJ, Palau C. et al . Altered neural response of the appetitive emotional system in cocaine addiction: an fMRI Study.  Addict Biol. 2010;  15 (4) 504-516
  CrossrefPubMedGoogle Scholar
• 16 Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.  J Clin Psychiatry. 2008;  69 783-789
  CrossrefPubMedGoogle Scholar
• 17 Hollander E, Pallanti S, Allen A. et al . Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?.  Am J Psychiatry. 2005;  162 137-145
  CrossrefPubMedGoogle Scholar
• 18 Grant JE, Kim SW, Potenza MN. et al . Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial.  Int Clin Psychopharmacol. 2003;  18 243-249
  CrossrefPubMedGoogle Scholar
• 19 Grant JE, Kim EW, Odlaug BL. N-Acetylcysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.  Biol Psychiatry. 2007;  62 652-657
  CrossrefPubMedGoogle Scholar
• 20 Suh JJ, Pettinati HM, Kampman KM. et al . The status of disulfiram: a half of a century later.  J Clin Psychopharmacol. 2006;  26 290-302
  CrossrefPubMedGoogle Scholar
• 21 Barth KS, Malcolm RJ. Disulfiram: an old therapeutic with new applications.  CNS Neurol Disord Drug Targets. 2010;  9 5-12
  PubMedGoogle Scholar
• 22 Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction.  Neuropsychopharmacology. 2007;  32 1433-1451
  CrossrefPubMedGoogle Scholar
• 23 Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction.  Expert Opin Investig Drugs. 2002;  11 491-499
  CrossrefPubMedGoogle Scholar
• 24 Roy A, Adinoff B, Roehrich L. et al . Pathological gambling. A psychobiological study.  Arch Gen Psychiatry. 1988;  45 369-373
  CrossrefPubMedGoogle Scholar
• 25 Mutschler J, Bühler M, Diehl A. et al . Disulfiram, an old drug with new potential in the treatment of pathological gambling?.  Med Hypotheses. 2010;  74 209-210
  CrossrefPubMedGoogle Scholar
• 26 Mutschler J, Bühler M, Grosshans M. et al . Disulfiram, an option for the treatment of pathological gambling?.  Alcohol Alcohol. 2010;  45 214-216
  PubMedGoogle Scholar
• 27 Pani PP, Trogu E, Vacca R. et al . Disulfiram for the treatment of cocaine dependence.  Cochrane Database Syst Rev. 2010;  (1) CD007024
  PubMedGoogle Scholar
• 28 Pallanti S, DeCaria CM, Grant JE. et al . Reliability and validity of the pathological gambling adaptation of the Yale-Brown obsessive-compulsive scale (PG-YBOCS).  J Gambl Stud. 2005;  21 431-443
  CrossrefPubMedGoogle Scholar
• 29 Diehl A, Ulmer L, Mutschler J. et al . Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients.  Alcohol Alcohol. 2010;  45 271-277
  CrossrefPubMedGoogle Scholar
• 30 Krampe H, Stawicki S, Wagner T. et al . Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.  Alcohol Clin Exp Res. 2006;  30 86-95
  CrossrefPubMedGoogle Scholar
• 31 Li MY, Shen YC. Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram.  Prog Neuropsychopharmacol Biol Psychiatry. 2008;  32 311-312
  CrossrefPubMedGoogle Scholar
• 32 Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence.  Drug Saf. 1999;  20 427-435
  CrossrefPubMedGoogle Scholar
• 33 Hameedi FA, Rosen MI, McCance-Katz EF. et al . Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans.  Biol Psychiatry. 1995;  37 560-563
  CrossrefPubMedGoogle Scholar
• 34 Hall GW, Carriero NJ, Takushi RY. et al . Pathological gambling among cocaine-dependent outpatients.  Am J Psychiatry. 2000;  157 1127-1133
  CrossrefPubMedGoogle Scholar

Correspondence

C. A. MüllerMD 

Department of Psychiatry

CharitéCampus Mitte

Charité – Universitätsmedizin Berlin

Charitéplatz 1

10117 Berlin

Germany

Email: ch.mueller@charite.de